UPSTREAM BIO INC (UPB)
Health Care · Clinical-stage monoclonal antibody / TSLP-targeting biologics · NASDAQ
Upstream Bio is a clinical-stage biotech developing verekitug, a potentially best-in-class monoclonal antibody targeting the TSLP receptor for the treatment of severe respiratory inflammatory diseases.
What UPSTREAM BIO INC does
Upstream Bio is a clinical-stage biotechnology company developing verekitug, a monoclonal antibody that targets the TSLP receptor to treat inflammatory diseases, with an initial focus on severe respiratory disorders including severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD). The company has advanced verekitug into Phase 2 trials across these indications, with positive top-line results reported in CRSwNP and severe asthma, and plans to initiate Phase 3 trials in both indications in the first quarter of 2027. Verekitug is designed to be approximately 300-fold more potent than the approved TSLP ligand antagonist tezepelumab, enabling extended dosing intervals of up to 24 weeks compared to tezepelumab's four-week dosing schedule.
Themes: TSLP / inflammatory disease, Severe asthma treatment, Chronic rhinosinusitis with nasal polyps (CRSwNP), COPD treatment, Monoclonal antibodies / biologics, Clinical-stage biotech
Fundamentals
- Price$6.97 as of 2026-08-21 close
- Market cap$382M as of 2026-08-21
- 1-year return-60.7% 2025-08-21 close $17.74 → 2026-08-21 close $6.97
- P/En/a negative earnings
- Net margin-4719.0% as of 2026-08-24
- ROE-43.8% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+13.2% as of 2026-08-24
- Revenue CAGR (3y)+9.5% SEC XBRL
- Beta2.07 as of 2026-08-24
- Last reported earnings2026-08-11 SEC EDGAR Form 8-K (Item 2.02)
How UPB compares in its sector
- net profit marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How UPSTREAM BIO INC looks technically
UPSTREAM BIO INC (UPB) is trading 55.2% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 98 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 50, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 3 trading days ago. It is 79.3% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 55.2% below its 200-day average, the long-term trend line — a long-term downtrend | -55.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $6.85 | $6.85 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $15.56 | $15.56 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 10 calendar days ago — the swings before that are what the structure reading is measured on | 10 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 7.7. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 98 trading days ago — a "death cross", a bearish long-term signal | 98 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend) | 19.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 50, neither overbought (above 70) nor oversold (below 30) | 49.8 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($6.40 to $7.70) — its "stochastic" reading is 44 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 43.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 14 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $33.68 | $33.68 |
|---|---|---|
| From the 52-week high | it is 79.3% below its 52-week high (its highest price of the past year) | -79.3% |
| Above the 52-week low | it is 19.1% above its 52-week low (its lowest price of the past year) | +19.1% |
| Below the 52-week high | it is 79.3% below its highest point of the past year | 79.3% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day low about 47 trading days ago | 47 sessions |
| All-time high | its highest closing price on record is $33.68 (set on 2026-01-14) | $33.68 |
| Given back of the 52-week move | over the past year its closes ranged ($5.92 to $32.60), and it has recovered only a small part of its fall from last year’s high — 4% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $22.41 to $23.26. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 3.9% |
| From the all-time high | it is 79.3% below its all-time high | -79.3% |
| Nearest price level | it is trading 4.5% above a support level at $6.66 — a price it turned at twice since 2025-02-12, most recently on 2025-03-04. Since 2024-10-11 it has 1 such level below the current price and 8 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -4.5% |
| All-time low | its lowest closing price on record is $5.14 (set on 2025-04-09) | $5.14 |
| Above the all-time low | it is 35.6% above its all-time low | +35.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 80% of it) | 20th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.4385 between its high and its low — about 6.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.4385 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $6.16 and $7.53 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $6.16 – $6.85 – $7.53 |
| Typical daily range (% of price) | its price moves about 6.3% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.3% |
| Stretch from the 200-day average | it is trading 19.6 daily ranges below its 200-day average price (55.2% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 19.6 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.77× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 12.4% since the prior reading | -12.4% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a bearish engulfing | 8 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 8 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.9% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.9% |
|---|---|---|
| Open gap | it gapped 22.0% below the previous close 51 sessions ago and has not traded back through the level it left behind at 8.37 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -22.0% |
| Gap filled | a 2.8% gap up opened on 2026-08-19 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it took 1 session to close | 1 session ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 2.5 percentage points (the stock lost 0.1% while the market gained 2.3%) | -2.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 20.7 percentage points (the stock lost 17.6% while the market gained 3.1%) | -20.7% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 24.8 percentage points (the stock lost 13.7% while the market gained 11.1%) | -24.8% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 81.2 percentage points (the stock lost 60.7% while the market gained 20.5%) | -81.2% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a fresh 20-day high, MACD momentum is positive — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 3.3% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 14.9% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -3.3% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 39% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $11.42 — a volume-weighted average of daily closes over 150 sessions, not a true tick-by-tick VWAP. | -39.0% |
|---|
Price levels it has turned at before
UPB last closed at $6.97 on 2026-08-21. Since 2024-10-11 it has turned at 1 price below its last close and 8 above; the nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $6.66 | Support | 4.5% below the last close | turned there twice · 2025-02-12 to 2025-03-04 |
| $7.75 | Resistance | 11.1% above the last close | turned there twice · 2025-05-06 to 2026-08-11 |
| $9.65 | Resistance | 38.4% above the last close | turned there twice · 2025-05-12 to 2026-05-11 |
| $9.86 | Resistance | 41.5% above the last close | turned there twice · 2025-06-18 to 2026-03-17 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $7.70.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $7.70.
This reading has stood for 4 trading days, since 2026-08-18.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Broke out to a new 20-day high · trendless / choppy (low ADX) · Analyst price target recently CUT · lagging the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.56 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
- Mean price target$33.50 range $9.00 – $75.00; median $30.50
Analyst estimates, as of 2026-08-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for UPB
- Consensus EPS estimate-$0.7609 next reporting period, as of 2026-08-17
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Verekitug is still in Phase 2 development; clinical advancement to Phase 3 is uncertain, and clinical trial failures could halt development and deplete cash reserves.","Established competitor tezepelumab (Tezspire, marketed by Amgen/AstraZeneca) already approved and capturing significant market share in severe asthma; failure to differentiate verekitug on efficacy or safety could limit market adoption.","Company is pre-revenue from product sales (only collaboration revenue), with negative net margin of -4718.96% and significant cash burn; funding requirements for Phase 3 trials and commercialization are substantial and success depends on raising capital."]
What changed in the latest 10-Q
AI-assisted comparison of UPB's 10-Q filed 2026-05-13 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Reworded:
- Page number for 'Management's Discussion and Analysis of Financial Condition and Results of Operations' changed from 18 (filed 2025-11-05) to 16 (filed 2026-05-13)
- Page number for 'Quantitative and Qualitative Disclosures About Market Risk' changed from 29 (filed 2025-11-05) to 26 (filed 2026-05-13)
- Page number for 'Controls and Procedures' changed from 29 (filed 2025-11-05) to 26 (filed 2026-05-13)
- Page number for 'OTHER INFORMATION' changed from 31 (filed 2025-11-05) to 27 (filed 2026-05-13)
- Page number for 'Legal Proceedings' changed from 31 (filed 2025-11-05) to 27 (filed 2026-05-13)
- Notes:
- Only table of contents page numbers are visible in the provided excerpts; substantive MD&A content cannot be assessed from this comparison
- Page number changes typically reflect document length or formatting differences rather than content changes
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 5 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 5 sells ($30622) — 5 selling insiders
- Last 180 days0 buys · 6 sells ($38537) — 5 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-16. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about UPB's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding UPB as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 12,318,202
- Reported value $110,863,821
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
UPB had 3,648,558 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
UPB had 6.66% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.49 days to cover at the same settlement.
- Reported short interest (shares) 3,648,558
- Short interest (% of shares outstanding) 6.66%
- Prior settlement (shares) 3,618,151
- Reported change 0.84%
- Days to cover (reported) 7.49
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Amgen/AstraZeneca (tezepelumab/Tezspire)
- Dupilumab (Regeneron/Sanofi)
- Mepolizumab (GlaxoSmithKline)
- Reslizumab (Teva Pharmaceuticals)
- Benralizumab (AstraZeneca)
- Omalizumab (Novartis/Roche)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare UPB vs…
UPSTREAM BIO INC is found in…
Frequently asked questions
What does UPSTREAM BIO INC (UPB) do?
Upstream Bio is a clinical-stage biotechnology company developing verekitug, a monoclonal antibody that targets the TSLP receptor to treat inflammatory diseases, with an initial focus on severe respiratory disorders including severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD).
What sector is UPSTREAM BIO INC (UPB) in?
UPSTREAM BIO INC (UPB) is classified in the Health Care sector. Its industry is Clinical-stage monoclonal antibody / TSLP-targeting biologics. It trades on NASDAQ.
Who are UPSTREAM BIO INC's (UPB) competitors?
Notable peers of UPSTREAM BIO INC (UPB) include Amgen/AstraZeneca (tezepelumab/Tezspire), Dupilumab (Regeneron/Sanofi), Mepolizumab (GlaxoSmithKline), Reslizumab (Teva Pharmaceuticals) and Benralizumab (AstraZeneca). This peer set is informational only — not financial advice.
Is UPSTREAM BIO INC (UPB) overbought or oversold right now?
UPSTREAM BIO INC (UPB) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 50, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on UPB come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.